Performance differences seen in continuous glucose monitors

January 25, 2013
Performance differences seen in continuous glucose monitors
Continuous glucose monitoring devices vary in performance characteristics, according to a comparative effectiveness study published online Dec. 28 in Diabetes Care.

(HealthDay)—Continuous glucose monitoring (CGM) devices vary in performance characteristics, according to a comparative effectiveness study published online Dec. 28 in Diabetes Care.

Edward R. Damiano, Ph.D., from Boston University, and colleagues recruited six patients with (age 52 ± 14 years) to participate in two 51-hour closed-loop blood glucose control experiments. Subjects simultaneously wore three CGM devices—the Navigator (Abbott ), the Seven Plus (DexCom), and the Guardian ()—to obtain CGM glucose (CGMG) measurements. Measurements were paired with corresponding venous (PG) measurements (GlucoScout, International Biomedical) obtained every 15 min (2,360 values).

The researchers found that the Navigator had the best overall accuracy, with an aggregate mean absolute relative difference (MARD) of all paired points (PG-CGMG measurements) of 11.8 ± 11.1 percent and an average MARD across all 12 experiments of 11.8 ± 3.8 percent. The Seven Plus had an aggregate MARD of all paired points of 16.5 ± 17.8 percent and an average MARD across all 12 experiments of 16.5 ± 6.7 percent. For the Guardian, the corresponding figures were 20.3 ± 18.0 percent and 20.2 ± 6.8 percent. Reliability, as measured by data reporting percentages, was 76 percent for the Seven Plus and close to 100 percent for the Navigator and Guardian.

"The results of this head-to-head-to-head study reveal the Navigator was the most accurate and precise of the current generation of CGM devices, followed by the Seven Plus and the Guardian," the authors write.

International Biomedical provided GlucoScout monitors and technical assistance regarding their use.

Explore further: Study shows regular CGM use increases diabetes control for all age groups

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

MU researchers pioneer animal diabetes treatment

April 25, 2011

Studies show the incidence of diabetes in dogs has increased 200 percent over the past 30 years. Now, University of Missouri veterinarians have changed the way veterinarians treat diabetes in animals by adapting a device ...

Study assesses glucose monitoring trends in tweens

April 12, 2012

(HealthDay) -- During the transition to adolescence, children with type 1 diabetes monitor their blood glucose less frequently, resulting in significant increases in HbA1c levels, according to research published online April ...

ADA: Hypo-hyperglycemia minimizer system feasible

June 12, 2012

(HealthDay) -- The hypoglycemia-hyperglycemia minimizer (HHM) system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM), and software, is able to predict changes in blood glucose ...

Fasting plasma glucose beats HbA1c for diabetes screening

January 17, 2013

(HealthDay)—For patients without diabetes undergoing coronary angiography (CAG), fasting plasma glucose (FPG) performs better in diabetes screening than glycated hemoglobin (HbA1c), according to a study published online ...

Recommended for you

Diets avoiding dry-cooked foods can protect against diabetes

August 24, 2016

Simple changes in how we cook could go a long way towards preventing diabetes, say researchers at the Icahn School of Medicine at Mount Sinai. A new randomized controlled trial, published online July 29 in the journal Diabetologia, ...

New study reveals a novel protein linked to type 2 diabetes

August 16, 2016

Findings from Boston University School of Medicine (BUSM), which appear in eLife, provide a possible explanation as to why most people who are obese develop insulin resistance and type 2 diabetes. A minority of obese individuals, ...

Gene variant explains differences in diabetes drug response

August 9, 2016

The first results from a large international study of patients taking metformin, the world's most commonly used type 2 diabetes drug, reveal genetic differences among patients that may explain why some respond much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.